Indian Journal of Pharmaceutical Chemistry and Analytical Techniques (IJPCAT)
ISSN: 3049-3765 | Vol. 02, Issue-04, July-August, 2026, pp. 52-65
https://ijpcat.com/1

Role of Analytical Chemistry in Drug Metabolism and Pharmacokinetics Studies

Neetu Gupta[1], Jagriti Chandrakar[1], Nishant Kumar Singh[2], Srijan Kumar Sahu[2], Vinay Sagar Verma[1*]

[1]Kamla Institute of Pharmaceutical Sciences, Junwani, Bhilai,490020 Durg (Dt), Chhattisgarh, India
[2]Perpetual Association of Professional Innovations, Durg, Chhattisgarh, India. Pin-491001, India

***Corresponding Author E-mail: vinaysagarverma@gmail.com**

Abstract:

The preclinical drug development is based on drug metabolism and pharmacokinetics (DMPK), which defines the efficacy, safety, and dosage profile of therapeutic agents. Analytical chemistry has been crucial in the understanding of absorption, distribution, metabolism, and excretion (ADME) in animal model studies and therefore offers a useful way of understanding pharmacokinetic pathways and metabolic mechanisms. This review examines the influential works of analytical chemistry in the field of DMPK research with focus on chromatographic and spectroscopic methods, bioanalytical methods, and more advanced metabolite profiling using the advanced mass spectrometry. It also considers the weaknesses of current methods of analysis, issues in animal model research, and how current methods can be improved to achieve more accurate, sensitive, and translational quality of analytical analysis in preclinical drug metabolism and pharmacokinetics.

Keywords: Analytical chemistry, Drug metabolism, Pharmacokinetics, ADME, Chromatography, Mass spectrometry, Bioanalytical techniques

Received: May 11, 2026 **Revised: June 23, 2026** **Accepted: 12 July, 2026** **Published: August 5, 2026**

DOI: https://doi.org/10.64062/IJPCAT.Vol2.Issue4.3

https://ijpcat.com/index.php/1/issue/archive

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. ***(https://creativecommons.org/licenses/by-nc/4.0/)***

1. INTRODUCTION

The creation of new therapeutic agents is a complex process, which requires a thorough insight into the interactions of drugs with biological systems. Drug metabolism and pharmacokinetics (DMPK) are the most important components of this effort, which refer to the absorption, distribution, metabolism and excretion (ADME) of pharmaceutical compounds together [1]. The biochemical changes that drugs are exposed to in living organisms are the subject of drug metabolism, and the quantitative study of their transport through the body is pharmacokinetics. Proper characterization of these processes is the key to the ability to estimate drug efficacy,

safety, bioavailability, as well as the proper dosing strategies before the clinical trial. DMPK research is heavily dependent on analytical chemistry, which provides potent methods, including high-performance liquid chromatography (HPLC), mass spectrometry (MS), gas chromatography (GC), and nuclear magnetic resonance (NMR) to detect, identify, and determine drugs and their products in complex biomatrices. These tools of analysis can be used in preclinical animal research to clarify pharmacokinetic profiles, disclose metabolic routes, and a probable toxicity[2]. With such advanced analytical approaches combined with animal studies, researchers are able to enhance drug development initiatives in a more robust and effective manner to guarantee that good therapeutic prospects are properly tested on safety and effectiveness prior to them being related to clinical utilization[3].

1.1.Background of the study

Invention of new therapeutic agents is a very multidisciplinary challenging task that requires a deep insight into the interaction and processes of drugs on the biological systems. The most important part of this process is the following fields of research which are drug metabolism and pharmacokinetics (DMPK) which together can present the framework of the absorption, distribution, metabolism, and excretion (ADME) of pharmaceutical compounds. Drug metabolism refers to the biochemical and enzymatic processes, which are experienced by a drug within the body and may lead to the generation of active, inactive, and even toxic, metabolites[4]. Pharmacokinetics, conversely, measures the change in drug numbers in the body over time and provides the most important information on the onset of action, duration, and possible accumulation of drugs in tissues. Combined, the parameters play vital roles in determining the efficacy of the drugs, their safety, bioavailability, and also in developing the drugs with regards to the right dosage schedule before a compound is taken to clinical trials.

DMPK research is built upon analytical chemistry which offers the advanced methodology that is needed to detect, identify, and quantify drugs and their metabolites in highly complex biological samples, such as blood, plasma, urine, and tissue samples. Advanced methods like the use of HPLC, ultra-performance liquid chromatography (UPLC), GC, MS and NMR spectroscopy have radically improved the accuracy, sensitivity, and the resolving power of such analyses. When applied in animal-based preclinical research, these tools enable scholars to develop comprehensive pharmacokinetic profiles, map out complex metabolic pathways and anticipate the toxicity of candidate molecules. In addition, the combination of these analytical methods enhance the assessment of species-sensitive variations in drug metabolism, assists in the optimization of dosing, and enhances the translational significance of preclinical results, as a result, the gap between laboratory studies and clinical execution is closed[5].

1.2.Objectives of the Review

The primary objective of this review is to provide a comprehensive and critical analysis of the role of analytical chemistry in drug metabolism and pharmacokinetics studies, with particular emphasis on animal-based research models. It aims to:

1. To summarize key analytical methodologies applied in DMPK studies.
2. To discuss recent advancements in chromatographic, spectroscopic, and bioanalytical techniques.
3. To evaluate the strengths and limitations of current approaches used in animal models.

4. To explore the implications of these methodologies for preclinical drug development and translational research.
5. To suggest potential future directions for enhancing the accuracy, sensitivity, and predictive value of analytical tools in DMPK studies.

1.3.Importance of the Topic

DMPK studies cannot be composed without the integration of analytical chemistry into their studies. It would not be possible to evaluate the action of a drug in the living systems without proper analytical techniques and even to evaluate whether the drug possesses the pharmacological characteristics required to proceed to clinical stages. Preclinical research on animals is a critical aspect that provides information on pharmacokinetics and metabolism of drugs that cannot be acquired using in vitro approaches only[6]. Analytical chemistry is the bridge between laboratory experimentation and pharmacological analysis by offering measurements of drug behavior in vivo, which are reliable, reproducible, and sensitive.

In addition, emerging complexity of contemporary drug candidates, including small molecules, biologics and nanomedicine formulations, requires sustained innovation in methods of analysis. The knowledge of the importance of analytical chemistry in DMPK can not only enable safer and more efficient drug development but can also respond to regulatory demands and speed up the process of converting promising compounds into therapeutic use.



Figure 1: Drug Metabolism & Pharmacokinetics

2. ANALYTICAL CHEMISTRY IN DRUG METABOLISM STUDIES

A basic issue in pharmacokinetics is the metabolism of drugs, which controls the chemical and enzymatic conversion of a drug in living organisms, which would then determine its therapeutic efficacy, safety and efficacy[7]. They may lead to active metabolites, inactive compounds or even toxic by-products and it is important that these metabolic processes are well characterized during preclinical evaluation. In preclinical research, especially involving the use of animal models, analytical chemistry is especially very important, as it gives the means to identify, detect, and quantify these metabolic reactions with great precision. HPLC, UPLC, GC, MS, and NMR spectroscopy are some of the techniques through which researchers can determine the fate of drugs in complicated biological samples, including blood, urine, and tissue samples.

All of the analytical technologies have their own strengths, be it in sensitivity, specificity, speed, or in explicating the molecular structures, and permit in-depth profiling of drug metabolism. Combining these methodologies in preclinical studies would enable researchers to have an insight into pharmacokinetic behavior and predict the possible adverse effects and optimize dosing regimens and aid in creating safer and more effective therapeutic agents.

- **Chromatographic Techniques (HPLC, UPLC, GC)**

The mainstay of drug metabolism analysis has been chromatography that provides powerful drug/metabolite separation and quantification. The HPLC enjoys wide use in analysing plasma, urine and tissue samples with its reproducibility and ability to handle a large variety of compounds. The invention of UPLC has increased even more the resolution, speed, and sensitivity, allowing finding the metabolites in the traces of their content. GC especially in combination with mass spectrometry is useful in volatile as well as thermally stable compounds. Together, the chromatographic methods demonstrate the background information needed to comprehend drug metabolism in the animal models[8].

- **Mass Spectrometry (LC–MS/MS, GC–MS)**

Drug metabolism has been transformed by the introduction of MS because of high sensitivity and specificity. Liquid chromatography (LC) has been developed to efficiently separate and structurally elucidate massive mixtures of metabolites, even at low concentrations. LC has been developed to effectively separate and structurally elucidate large mixtures of metabolites, even in low concentrations[9]. Gas chromatography- mass spectrometry (GC-MS) is especially effective in volatile compounds or derivatives which need to be derivatized. The development of high-resolution mass spectrometry (HRMS), including time-of-flight (TOF) and orbitrap spectrometers, have currently permitted high-quality measurements of mass, which has made it possible to identify small metabolites, which have been difficult to detect previously. This has particular importance in the detection of reactive intermediates which can lead to drug-induced toxicity.

- **Spectroscopic Methods (NMR, UV–Vis, IR)**

The MS technology has transformed the research of drug metabolism since it is very sensitive and specific. In LC-Tandem Mass Spectrometry, complex mixtures of metabolites are separated simultaneously and their structure elucidated, even with low concentrations. GC-MS is especially effective in volatile metabolites/compounds that need derivatization. Developments in HRMS, including TOF and orbitrap systems, have currently made it possible to measure a mass and this has led to the detection of minor metabolites that were not previously detected. This is particularly important in the detection of reactive intermediates in the process of drug-induced toxicity[10].

- **In vitro–In vivo Correlation (IVIVC)**

One of the critical points in the drug metabolism research is to establish the correlations between in vivo and in vitro results. Analytical chemistry is a vital component in this process as it supplies quantitative data on what connects the enzyme studies done in vitro to the entire organism pharmacokinetic profiles in animal models. IVIVC can assist in forecasting drug bioavailability, dosage form optimization and predicting potential metabolic bottlenecks prior to clinical pharmacology. This combination means that preclinical investigations do not only produce credible information, but also provide the rational choices on drug development.

3. ANALYTICAL CHEMISTRY IN PHARMACOKINETIC STUDIES

Pharmacokinetics (PK) is one of the core disciplines of pharmacology that use quantitative methods to characterize the pathways of drug absorption into the bloodstream, distribution across tissues, metabolic processes to active or inactive forms and excretion across living systems. Detailed knowledge of such processes is essential in identifying the best dose schedules, reducing the undesirable actions, effects of drug-drug interactions, and determining the overall therapeutic performance of the newly developed pharmaceutical drugs. Proper PK assessment enables researchers to determine how a drug acts with time in the body that is important in safety and efficacy assessment before its use in clinical treatment.

Pharmacokinetic studies would not be possible without analytical chemistry, which provides the means of measuring the concentrations of drugs in complex biological fluids like plasma, serum, urine and tissue samples to a high sensitivity, reliably, and reproducibly. Such methods as HPLC, UPLC, GC, and MS allow the accurate determination of drugs and their metabolites even at the traces. These data analysis methods are used in preclinical animal models to characterize pharmacokinetic parameters (clearance, half-life, volume of distribution and bioavailability) in detail. Moreover, through combining sophisticated sample preparation techniques and biomarker validation standards, analytical chemistry gives PK data a solid foundation to support preclinical decision making and translational research and make them accurate and reproducible.

- **Bioanalytical Method Development**

One of the pillars of pharmacokinetics is the establishment and establishment of bioanalytical procedures that can effectively measure drugs and their metabolites. Validated protocols are specific (can identify the drug with presence of biological matrices), accurate (measures values close to actual concentrations), precise (consistency of measurements), and linear (response proportional to concentrations over a range of concentrations). In order to develop sensitive and robust bioanalytical mechanisms to estimate drug concentrations in animal blood, plasma, and tissues, HPLC, UPLC and LC, MS/MS are among the techniques that are popular. To make the pharmacokinetic parameters obtained in such measurements reliable and reproducible, it is essential to make sure that the method of their determination has been properly validated.

- **Sample Preparation Approaches**

Proteins, lipids and other interference substances will be present in the biological matrices including plasma, urine, and tissue homogenates, which may impair the accuracy of the analysis. Hence, sample preparation is required to be done effectively prior to analysis. Common approaches include:

  - Protein Precipitation: This is simple and quick; it usually involves the use of organic solvents (e.g. acetonitrile or methanol) to precipitate proteins but leave the analytes.
  - Solid-Phase Extraction (SPE): It utilizes the selectivity of sorbent material to extract drugs and other metabolites and enhances sensitivity and minimizes the effects of the matrix.
  - Liquid-Liquid Extraction (LLE): Separates the analytes according to differences in their solubility in immiscible solvents, which can be used with non-polar compounds.

Optimal sample preparation will increase the recovery, decrease variability in analysis and increase the quality of pharmacokinetic data.

- **Pharmacokinetic Parameters**

The quantitative basis of calculating critical pharmacokinetic parameters in animal models using analytical chemistry includes:

- **Clearance (CL):** This is the rate at which a drug is removed out of the body.
- **Half-life (t 1 2):** The time that it takes the drug to decrease by half.
- **Volume of Distribution (Vd):** This is the apparent space within the body that can accommodate the drug distribution.
- **Bioavailability (F):** Percentage of drug administered getting to systemic circulation.

By measuring these parameters correctly, researchers can therefore predict dosage regimen, determine the risk of accumulation and the species-specific variations in drug handling.

- **Population PK Modeling**

In addition to individual animal research, analysis data may also be utilized in population pharmacokinetic (PopPK) modeling, which has been a vital resource in the contemporary drug development. PopPK involves a combination of computational algorithm and sophisticated statistical techniques in the measurement and analysis of inter-individual differences in drug absorption, distribution, metabolism and excretion. This method enables the researcher to help determine the effects of intrinsic factors, including age, body weight, sex, genetic polymorphisms, and organ functionality and extrinsic factors, including diet, co-administered drugs, and disease conditions on drug disposition within a population. With the ability to combine exact analytical measures acquired through preclinical trials with complex PopPK models, scientists are able to make predictions on the behaviour of drugs in greater and less uniform groups, even prior to the commencement of some clinical trials.

This combination increases the translational applicability of the pharmacokinetic work, allows more informed dosing approaches, reduces the risk of adverse events and allows one to design clinical trials in a more rational way. Also, PopPK modeling will be useful in identifying subpopulations that might need specific therapeutic treatments and enhances the safety and efficacy of candidate drugs. In general, the combination of analytical chemistry and population-based modeling can be a strong framework to help bridge preclinical discoveries to human pharmacology and personalized medicine.

Table 1: Summary of Literature on Drug Metabolism and Pharmacokinetics

Author Name	Topic Covered	Research Study Title
Javdan et al. (2020)[11]	Personalized drug metabolism	Individual mapping of the human gut microbiome drug metabolism.
Ahmed et al. (2016)[12]	Pharmacogenomics and precision medicine	Drug metabolizing enzyme and transporter pharmacogenomics: its implication on precision medicine.
Bizzarri et al. (2016)[13]	Pharmacodynamics and pharmacokinetics of inositols	Inositol(s) pharmacodynamics and pharmacokinetics in health and disease.

Zhao et al. (2021)[14]	Cytochrome P450 enzymes in humans	Human cytochrome P450 and drug metabolism.
Adiwidjaja et al. (2017)[15]	Curcumin pharmacokinetics and drug interactions	Clinically-promising anti-cancer agent Curcumin: pharmacokinetics and drug interactions.
Zimmermann et al. (2019)[16]	Host vs microbiome contributions to pharmacokinetics	Disentangling host and microbiome drug pharmacokinetics and toxicity.

4. APPLICATIONS IN PRECLINICAL ANIMAL STUDIES

Preclinical phase involves animal studies which are crucial steps in drug development, as animal studies present crucial information on absorption, distribution, metabolism and excretion (ADME) of candidate drugs. These are experiments that provide an in vivo setting that is paramount in cognising the behavior of a drug in the complex biological systems before it is administered on a human being[17]. Analytical chemistry is the primary section of preclinical work and it enables the establishment of the concentration of drugs in biological samples (blood, plasma, urine, and tissues) with high accuracy[18]. By placing high-performance liquid chromatography (HPLC), gas chromatography (GC), mass spectrometry (MS), nuclear magnetic resonance (NMR), and ultra-performance liquid chromatography (UPLC) in high regard, researchers can sense and observe metabolites, clarify metabolism, and create a complete pharmacokinetic description in diverse species of animals[19].

This specific description is useful in identifying key values like bioavailability, half-life, clearance and volume of distribution, which would be necessary to optimize dosage schedules and to anticipate possible toxicities. In addition, combining analytical measurements with preclinical animal research enables the investigator to identify species-specific differences in metabolism during the drug, predict human health effects, and direct the development of safe and effective clinical trials. In pharmacology, preclinical studies will establish a rigorous foundation of translational studies by integrating both experimental and sophisticated analytical technology, so that only promising drugs candidates proceed through the next phase of drug development[20].

- **Rodent Models**

The most widely used species in preclinical DMPK studies are rodents, such as mice and rats, as they are economical to use, easy to manipulate, and their physiology is well-characterized. Tools like HPLC, LC-MS/MS, and NMR are consistently used to determine the concentration of the drug in plasma, urine, and tissues, which help in the in-depth explanation of the metabolic pathway. Dose-response relationship is also evaluable in these kinds of studies and is used by researchers to optimize the dosage regimens and what safety concerns might arise during early development stages[21]. The reproducibility and genetic homogeneity of rodent models is that they are perfect to carry out mechanistic investigations of metabolism and drug clearance.

- **Non-Rodent Models (Dogs, Rabbits, Primates)**

Non-rodent models such as dogs, rabbits, and non-human primates are used to give more predictive data on comparative metabolism more relevant to human pharmacokinetics. Analytical chemistry aids such studies by precisely determining the concentration of drugs and the metabolic profile of the drug making cross-species extrapolation of pharmacokinetic data possible. Non-rodent models are also essential in determining species-specific variations in drug metabolism, bioavailability, and toxicity; this might not be clear in rodent models. Such a comparative strategy increases the translational outcome of preclinical results[22].

- **Metabolite Identification**

Determining and describing the drug metabolites is an essential aspect of the preclinical trials. Reactive intermediates and minor metabolites can be detected in animal samples by the use of analytical techniques, such as LC165, MS/MS and HRMS. The study of the generation of these metabolites is also necessary in anticipating any future toxicity, safety margin and structuring safer compounds prior to the development of clinical trials. Moreover, metabolite profiling provides regulatory submissions and risk assessment strategies, which ensure that candidate drugs pass safety and efficacy tests[23].

The preclinical animal experiments that may be done with the help of advanced analytical chemistry give a very detailed view of drug metabolism and pharmacokinetics. Rodent models can be useful in mechanistic studies and dose-response, but non-rodent species provide more translational information with respect to human beings[24]. The predictability of these studies is also increased by metabolite identification to indicate toxicities. All these applications highlight the inseparable nature of analytical chemistry in drug development at the preclinical levels so that candidate molecules are thoroughly scrutinized prior to their progression into clinical phases[25].

5. ADVANCES IN ANALYTICAL TOOLS FOR DMPK

The past few years have seen tremendous technological developments in the field of drug metabolism and pharmacokinetics (DMPK) that have been driven by developments in the analytical chemistry. Modern methods of analysis have greatly increased the level of sensitivity, resolution and throughput of drug analysis enabling researchers to profile the ADME of pharmaceutical compounds with such precision never before achievable. The developments in animal models during preclinical stages allow detailed monitoring of drug concentrations with time, metabolites and complex metabolic pathways that were hard to analyze before[26].

Rapid high-throughput analyses using techniques like UPLC, tandem MS, high-resolution NMR spectroscopy and advanced bioanalytical assays have now been practiced and now have the ability to reduce the sample requirements. Not only do these advances enhance the speed of preclinical research, but they also increase the accuracy of pharmacokinetic extrapolations, ease early identification of potential drug toxicities, and allow the efficient and rational development of safer and therapeutic agents. DMPK studies have thus been inseparably integrated with the state of the art analytical chemistry to form a bridge between laboratory experimentation and translational research since this has become indispensable to contemporary drug discovery and development[27].

- **High-Resolution Mass Spectrometry (HRMS)**

HRMS has changed the paradigm of drug metabolism research in two important aspects: it facilitates an untargeted metabolomics approach and allows the sensitive mass determination of both known and unknown metabolites. Methods like time-of-flight (TOF) and Orbitrap MS enable a researcher to find small or reactive metabolites that may have once remained unobservable and offer further understanding of metabolism and possible toxicities. The simultaneous identification/quantification of HRMS makes it an instrument of studies of preclinical metabolism in general[28].

- **Microdialysis Coupled with LC-MS**

Microdialysis is a technique that involves minimal invasiveness and together with the LC-MS method to monitor the concentration of drug in certain tissues which makes it possible to monitor real-time drug concentration in some tissues. This method gives dynamic pharmacokinetic data at the site of action, which gives more precise testing of the dispersion of drugs and tissue pervasion. Microdialysis has found application specifically in neuropharmacology and oncology research in which tissue-specific monitoring of drugs is essential in studying the effects of a given therapeutic dosage.

- **Nanotechnology-Based Sensors**

Since the introduction of nanotechnology in the field of analytical chemistry, sensors capable of detecting drugs in minute quantities and miniaturization of the sensors have emerged[29]. Plates using nanotechnology like nanosensors and nanosensors using biosensors, enable the rapid and real-time measurement of drugs and metabolites in biological media. They control sample volumes (down to very low levels), are sensitive (enhancing sensitivity), and can be used point-of use in preclinical studies and this should be considered a promising avenue in future DMPK research.

- **Automation and High-Throughput Screening**

The efficacy of preclinical DMPK studies has been raised dramatically by novel technologies in automation and high-throughput screening (HTS). Automated sample handling, data analysis, and sample preparation minimize error on humans and enhance reproducibility, and the spanning of multiple conditions or compounds at once are made possible by HTS. The identification of the metabolic profiles, pharmacological parameters and any safety issues is speeded up by these tools and it simplifies the process of development of the drug[30].

There have also been recent improvements in analytical facilities, such as HRMS, microdialysis-LC-MS, nanotechnology-modified sensors, and automation: greatly boosting the preclinical DMPK research capabilities. These innovations offer more focused, sensitive and dynamic data about drug metabolism and pharmacokinetics and enhance the validity of preclinical results and make more decisions about optimal decisions in first drug development.

6. DISCUSSION

It can be seen through the review of analytical chemistry solutions within drug development and pharmacology (DMPK) that chromatographic and mass spectrometric methods remain on the forefront of preclinical investigations[31]. These techniques are highly sensitive, specific and reproducible in the analysis of drug concentration and metabolites present in body samples. Methods, including HPLC, LC, MS/MS, high-resolution, and MS, have facilitated the exact characterization of sophisticated metabolic pathways, and spectroscopic schemes completed have been used to provide the structural validation of metabolites. In addition, microdialysis

development over time, nanotechnology sensors, and automation have enabled dynamical data of the drug distribution and high-throughput analysis, resulting in a higher level in the profoundness of investigation of preclinical research. This analysis means that a complete picture of absorption, distribution, metabolism, and excretion (ADME) occurs when analytical chemistry is incorporated in the models that involve animal test subjects, thus being essential in optimizing dosage regimens, anticipating safety, and determining drug design. These analytical data can be further elaborated and enhanced by the use of population PK modeling, which makes researchers appreciate the variability of individual subjects and species[32].

6.1.Implications and Significance

The results emphasize how analytics chemistry is critical in making the interface between chemistry and biology relevant in the field of preclinical drug research. Analytical methods based on the services that offer reliable quantitative and qualitative data on the behavior of different drugs is underlying the creation of safer, more effective therapeutic agents[33]. Such methods can regulate decisions on control, and enhance translative implications of preclinical trials and minimize the risk of adverse events during subsequent clinical trials. In addition, some newer analysis tools like high-resolution mass spectrometry and those operating based on nanotechnology are more predictive than earlier preclinical research studies, assists in early discerning possible toxicity and metabolite associated safety concerns[34].

6.2.Gaps and Future Research Directions

Although these have been achieved, there are still several gaps in preclinical DMPK studies:

1. **Matrix Interferences and Low-Abundance Metabolites:** Existing analytical methods can have a challenge in detecting very low-density metabolites or this technique can be biologically challenging due to complex biosets, possibly resulting in insufficient metabolic profiling.
2. **Limitations in Ethics and Translational Biases:** There is ethical aspect that utilization of animal models invoke that the aspect presents interspecies variations that restrict the chance of extrapolating the research findings to human pharmacokinetics.
3. **Information corridoring and complexities:** The more complex sets of analytical information are needed, the more refined computing tools are required to read multidimensional information more productively, which speaks of artificial intelligence (AI) and machine learning.

6.3.Future research should aim to:

- Enhance the sensitivity and specificity of analytical tools to capture minor and reactive metabolites.
- Develop non-invasive and minimally invasive sampling techniques, such as in vivo microdialysis or wearable nanosensors, to reduce reliance on terminal animal studies.
- Integrate AI-driven data analysis and predictive modeling to improve the translation of animal DMPK data to human applications.
- Explore cross-species and in vitro–in vivo correlation strategies to better predict human pharmacokinetics from preclinical data.

Overall, addressing these gaps will strengthen the predictive power of preclinical studies, streamline drug development, and ensure more efficient, safe, and effective translation from laboratory research to clinical application.

7. CONCLUSION

Drug metabolism and pharmacokinetics (DMPK) studies rely greatly on analytical chemistry, especially when applied to animal models in preclinical studies. Through advanced form of chromatograph, spectroscopic, mass spectrometric methods, researchers can have a comprehensive and precise characterization of absorption, distribution, metabolism and excretion (ADME) properties of a drug. Such methodologies can be used to accurately determine drug concentrations in biologic samples (plasma, urine, and tissue samples), identify and structurally clarify metabolites. The insights are imperative to assess the profile of safety of any candidate compound, identify their efficacy, or adjusting their dosing regimens. In addition, analytical chemistry offers the means which will support the ability to track dynamic metabolism, the ability to identify metabolites at low concentration, or employees in reactive states, and in vitro-in vivo correlations to increase the relevance of preclinical data on the intact organism. All these abilities combined guarantee that the potential therapeutic agents are carefully evaluated, and there are lower chances of negative effects in future developmental stages, as well as justify rational development of the safer and more active drugs.

7.1. Importance of the Review:

- Presents the irreplaceable role of analytical chemistry in preclinical DMPK investigation.
- Illustrates the extent to which analytical techniques have a unifying effect on chemistry and biology to produce reliable, reproducible and translational data.
- Demonstrates that superior analytical systems, which are coupled with a solid experimental design, increase predictive capability and knowledge of pharmacokinetic variability.

7.2. Recommendations:

- Develop exceptionally sensitive, quick and least invasive methods of analysis of preclinical studies.
- Install the technology of real-time monitoring, i.e. microdialysis and sensors based on nanotechnology.
- Use data analysis based on AI to enhance interpretation and predictive modeling.
- Concentrate on the strategies to increase the translational applicability of animal-to-clinical outcomes, which will aid in the development of safer and more powerful therapeutics.

REFERENCES

1. Zhang, Z., & Tang, W. (2018). Drug metabolism in drug discovery and development. Acta Pharmaceutica Sinica B, 8(5), 721-732.
2. Coleman, M. D. (2020). Human drug metabolism. Wiley Blackwell.
3. Di, L. (2019). The impact of carboxylesterases in drug metabolism and pharmacokinetics. Current drug metabolism, 20(2), 91-102.
4. Pike, A., Williamson, B., Harlfinger, S., Martin, S., & McGinnity, D. F. (2020). Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discovery Today, 25(10), 1793-1800.
5. Huang, T., Liu, Y., & Zhang, C. (2019). Pharmacokinetics and bioavailability enhancement of baicalin: a review. European Journal of Drug Metabolism and Pharmacokinetics, 44(2), 159-168.
6. Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., ... & Schneider, G. (2015). Predicting drug metabolism: experiment and/or computation?. Nature reviews Drug discovery, 14(6), 387-404.
7. Riva, A., Ronchi, M., Petrangolini, G., Bosisio, S., & Allegrini, P. (2019). Improved oral absorption of quercetin from quercetin phytosome®, a new delivery system based on food grade lecithin. European journal of drug metabolism and pharmacokinetics, 44(2), 169-177.
8. Li, H., He, J., & Jia, W. (2016). The influence of gut microbiota on drug metabolism and toxicity. Expert opinion on drug metabolism & toxicology, 12(1), 31-40.
9. Almazroo, O. A., Miah, M. K., & Venkataramanan, R. (2017). Drug metabolism in the liver. Clinics in liver disease, 21(1), 1-20.
10. Kapungu, N. N., Li, X., Nhachi, C., Masimirembwa, C., & Thelingwani, R. S. (2020). In vitro and in vivo human metabolism and pharmacokinetics of S-and R-praziquantel. Pharmacology research & perspectives, 8(4), e00618.
11. Javdan, B., Lopez, J. G., Chankhamjon, P., Lee, Y. C. J., Hull, R., Wu, Q., ... & Donia, M. S. (2020). Personalized mapping of drug metabolism by the human gut microbiome. Cell, 181(7), 1661-1679.
12. Ahmed, S., Zhou, Z., Zhou, J., & Chen, S. Q. (2016). Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics, proteomics & bioinformatics, 14(5), 298-313.
13. Bizzarri, M., Fuso, A., Dinicola, S., Cucina, A., & Bevilacqua, A. (2016). Pharmacodynamics and pharmacokinetics of inositol (s) in health and disease. Expert opinion on drug metabolism & toxicology, 12(10), 1181-1196.
14. Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., ... & Qin, S. (2021). Cytochrome P450 enzymes and drug metabolism in humans. International journal of molecular sciences, 22(23), 12808.
15. Adiwidjaja, J., McLachlan, A. J., & Boddy, A. V. (2017). Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions. Expert opinion on drug metabolism & toxicology, 13(9), 953-972.
16. Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019). Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science, 363(6427), eaat9931.

17. Van den Anker, J., Reed, M. D., Allegaert, K., & Kearns, G. L. (2018). Developmental changes in pharmacokinetics and pharmacodynamics. The Journal of Clinical Pharmacology, 58, S10-S25.
18. Verma VS, Sahu M. Synthesis And Characterization of NovelOrganometallic Complexes for CatalyticApplications. Journal of Pharmaceutical Research and Integrated Medical Sciences. 2025;2(4):60-70. Accessed January 9, 2026.
19. Kumar, D. . (2025). Applications of Quantum Chemistry in Molecular Spectroscopy and Reactivity. Journal of Pharmaceutical Research and Integrated Medical Sciences, 2(4), 31-48.
20. Tracy, T. S., Chaudhry, A. S., Prasad, B., Thummel, K. E., Schuetz, E. G., Zhong, X. B., ... & Lin, Y. S. (2016). Interindividual variability in cytochrome P450–mediated drug metabolism. Drug Metabolism and Disposition, 44(3), 343-351.
21. Andrade, E. L., Bento, A. F., Cavalli, J., Oliveira, S. K., Schwanke, R. C., Siqueira, J. M., ... & Calixto, J. B. (2016). Non-clinical studies in the process of new drug development-Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Brazilian journal of medical and biological research, 49(12), e5646.
22. Lauschke, V. M., Hendriks, D. F., Bell, C. C., Andersson, T. B., & Ingelman-Sundberg, M. (2016). Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chemical research in toxicology, 29(12), 1936-1955.
23. Vale, N., Gouveia, M. J., Rinaldi, G., Brindley, P. J., Gärtner, F., & Correia da Costa, J. M. (2017). Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrobial agents and chemotherapy, 61(5), 10-1128.
24. Verma VS, Sharma G. Determining Extractable Phthalates in Pharmaceutical Products Using Lcms/Ms. Indian Journal of Pharmaceutical Chemistry and Analytical Techniques. Published online June 2, 2025:38-50. Accessed January 9, 2026
25. Knights, K. M., Stresser, D. M., Miners, J. O., & Crespi, C. L. (2016). In vitro drug metabolism using liver microsomes. Current protocols in pharmacology, 74(1), 7-8.
26. Hellman, K., Aadal Nielsen, P., Ek, F., & Olsson, R. (2016). An ex vivo model for evaluating blood–brain barrier permeability, efflux, and drug Metabolism. ACS chemical neuroscience, 7(5), 668-680.
27. Tang, D., Chen, K., Huang, L., & Li, J. (2017). Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert opinion on drug metabolism & toxicology, 13(3), 323-330.
28. Wang, K., Feng, X., Chai, L., Cao, S., & Qiu, F. (2017). The metabolism of berberine and its contribution to the pharmacological effects. Drug metabolism reviews, 49(2), 139-157.
29. Feghali, M., Venkataramanan, R., & Caritis, S. (2015, November). Pharmacokinetics of drugs in pregnancy. In Seminars in perinatology (Vol. 39, No. 7, pp. 512-519). WB Saunders.
30. Hirota, T., Fujita, Y., & Ieiri, I. (2020). An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opinion on Drug Metabolism & Toxicology, 16(9), 809-822.
31. Yu, M., Liu, M., Zhang, W., & Ming, Y. (2018). Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Current drug metabolism, 19(6), 513-522.

32. Tsamandouras, N., Chen, W. L. K., Edington, C. D., Stokes, C. L., Griffith, L. G., & Cirit, M. (2017). Integrated gut and liver microphysiological systems for quantitative in vitro pharmacokinetic studies. The AAPS journal, 19(5), 1499-1512.
33. Vishwakarma EV, sakore A sakore, Singh RS, Dohre PD, Verma VSV. Targeting Inflammatory Pathways in Rheumatoid Arthritis Therapy. Journal of Pharmacology, Genetics and Molecular Biology. Published online December 24, 2025:18-34.
34. Chandrasekaran, B., Abed, S. N., Al-Attraqchi, O., Kuche, K., & Tekade, R. K. (2018). Computer-aided prediction of pharmacokinetic (ADMET) properties. In Dosage form design parameters (pp. 731-755). Academic Press.